2017-11-14 13:02:05

Enzymatica AB: Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses

Related content
29 nov - 
Enzymatica AB: Enzymaticas valberedning för årsstämman ..
14 nov - 
Enzymatica AB: Enzymatica presenterar resultat av studi..
09 nov - 
Enzymatica AB: Studie om ColdZyme - Den mest rekommende..

Press release

14 November, 2017

Enzymatica announces a study showing the ability of ColdZyme to deactivate major common cold viruses

Enzymatica announced today a publication in a peer-reviewed journal presenting the results of an in vitro study showing the ability of ColdZyme® Mouth Spray to deactivate the majority of viruses that cause the common cold. The study demonstrated that ColdZyme deactivated the viruses tested and prevented viral-induced cytopathic effect by 64.5 % to 99.9 %. These results indicate that ColdZyme might have clinical benefits in prevention and treatment of the common cold.

The medical device ColdZyme is a mouth spray that forms a barrier in the throat against common cold viruses. The barrier solution of the device is composed of glycerol and Atlantic cod trypsin. The study was conducted by an independent, accredited and certified laboratory. The goal of the study was to determine the ability of ColdZyme to deactivate several viruses known to cause the common cold in humans. A virucidal efficacy suspension test was conducted using ColdZyme against viruses belonging to the four virus families known to cause the majority of common colds1. ColdZyme deactivated rhinovirus type 1A by 91.7 %, rhinovirus type 42 by 92.8 %, human influenza A virus H3N2 by 96.9 %, respiratory syncytial virus (RSV) by 99.9 % and adenovirus type 2 by 64.5 %. Furthermore, cytotoxicity was not detected at any dilution or cell line tested.

"The results indicate that ColdZyme can offer a protective barrier against most common cold viruses, known to cause the disease. This is also supported by our previous clinical study, COLDPREV2, and our open label studies," says Fredrik Lindberg, CEO of Enzymatica.

The in vitro study was based on a standardised and validated methodology adapted to mimic the environment in vivo in the oropharynx (mouth and throat) where viruses take hold, invade and cause the disease.

The basis for the use of ColdZyme against the common cold is thought to partly depend on the ability of trypsin in cleaving proteins on the surface of viruses important for infection. This will inhibit viruses in binding to cellular receptors, thereby preventing or stopping the proliferation of an infection.

1) Stefansson, B., Gudmundsdottir, Á. and Clarsund, M. (2017). A medical device forming a protective barrier that deactivates four major common cold viruses. Virology: Research & Reviews, 1 (5). doi:10.15761/VRR.1000130

2)COLDPREV: https://doi.org/10.4236/ojrd.2017.74013

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 13:00 CET on November 14, 2017

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB

Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com   

About Enzymatica AB

Enzymatica AB is a life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in around ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information please visit: www.enzymatica.se

Enzymatica's Certified Adviser is Erik Penser Bank.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Enzymatica AB via Globenewswire

Postkommentar

Related debate

  • 1 vecka
  • 1 månad
  • 1 År
Ingen indlæg

Finansiell uppdatering för det fjärde kvartalet 2017

2018-01-17 08:30:03
Stockholm, 2018-01-17 08:30 CET (GLOBE NEWSWIRE) --   Lundin Petroleum AB (Lundin Petroleum) kommer att redovisa prospekteringskostnader om cirka 31 MUSD före skatt, en valutakursförlust om cirka 69 MUSD samt en förlust vid försäljning av tillgångar om 15 MUSD efter skatt för det fjärde kvartalet 2017.   Resultatet för det fjärde kvartalet 2017 kommer att påverkas av vissa prospekteringskostnader..

SEB: Fortsatt fallande boprisförväntningar bland hushållen

2018-01-15 08:30:09
SEB:s Boprisindikator forsätter att falla. Nedgången är 8 enheter jämfört med föregående månad och indikatorn hamnar nu på minus 13. Regionalt sticker Stockholm ut även denna månad jämfört med de övriga regionerna. Stockholm ligger lägst på minus 31 och övriga regioner i spannet 2 till minus 12. Hushållens förväntningar på reporäntans nivå om ett år stiger något jämfört med förra månaden frå..

Lindab International AB (publ): Ny koncernchef i Lindab

2018-01-12 07:40:14
Ola Ringdahl har av styrelsen i Lindab International AB utsetts till ny VD och koncernchef. Han kommer att ersätta Fredrik von Oelreich som sedan den 29 september 2017 är tillförordnad koncernchef. - Jag är mycket nöjd över att kunna presentera Ola Ringdahl som ny VD och koncernchef, säger styrelseordförande Peter Nilsson. Ola kommer genom sin kompetens och erfarenhet skapa framåtanda och ..

Mest lästa nyheter

  • 24 timmar
  • 48 timmar
  • 1 vecka
1
Rezidor Hotel Group presenterar sin 5-års plan vid investerardagen
2
SERSTECH AB: Serstech har fått sin första kund i Kina inom kvalitetskontroll
3
Hoylu AB: HOYLU OCH POLYMEDIA ERBJUDER PRODUKTLÖSNINGAR FÖR DEN VÄXANDE MARKNADEN FÖR SAMARBETE I RYSSLAND
4
Arc Aroma Pure AB : 180117 Arc Aroma Pure AB (publ) genomför en riktad kvittningsemission för ett lån om 17,5 MSEK
5
Klövern AB (publ): Klövern tecknar stamaktier i en riktad nyemission i Tobin Properties

Related stock quotes

Enzymatica AB 4,70 0,0% Aktiepriset oförändrad

Buy and sell signals

  • Trender
  • Pengamaskinen

Upphovsrätt Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Kursinformation levereras av Morningstar.
Alla kurser är fördröjda 15-20 minuter, enligt distributionsavtal fastställda av de olika börserna.
 
den 18 januari 2018 02:59:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180112.1 - EUROWEB5 - 2018-01-18 02:59:22 - 2018-01-18 02:59:22 - 2 - Website: OKAY